Literature DB >> 21346226

Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors.

Sebastian Barbus1, Björn Tews, Daniela Karra, Meinhard Hahn, Bernhard Radlwimmer, Nicolas Delhomme, Christian Hartmann, Jörg Felsberg, Dietmar Krex, Gabriele Schackert, Ramon Martinez, Guido Reifenberger, Peter Lichter.   

Abstract

Although the prognosis of most glioblastoma patients is poor, 3%-5% patients show long-term survival of 36 months or longer after diagnosis. To study the differences in activation of biochemical pathways, we performed mRNA and protein expression analyses of primary glioblastoma tissues from 11 long-term survivors (LTS; overall survival ≥ 36 months) and 12 short-term survivors (STS; overall survival ≤ 6 months). The mRNA expression ratio of the retinoic acid transporters fatty acid-binding protein 5 (FABP5) and cellular retinoic acid-binding protein 2 (CRABP2), which regulate the differential delivery of retinoic acid to either antioncogenic retinoic acid receptors or prooncogenic nuclear receptor peroxisome proliferator-activated receptor delta, was statistically significantly higher in the tumor tissues of STS than those of LTS (median ratio in STS tumors = 3.64, 10th-90th percentile = 1.43-4.54 vs median ratio in LTS tumors = 1.42, 10th-90th percentile = -0.98 to 2.59; P < .001). High FABP5 protein expression in STS tumors was associated with highly proliferating tumor cells and activation of 3-phosphoinositide-dependent protein kinase-1 and v-akt murine thymoma viral oncogene homolog. The data suggest that retinoic acid signaling activates different targets in glioblastomas from LTS and STS. All statistical tests were two-sided.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346226     DOI: 10.1093/jnci/djr036

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  19 in total

1.  Computationally simple analysis of matched, outcome-based studies of ordinal disease states.

Authors:  Rebecca A Betensky; Jackie Szymonifka; Eudocia Q Lee; Catherine L Nutt; Tracy T Batchelor
Journal:  Stat Med       Date:  2015-04-22       Impact factor: 2.373

Review 2.  Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: Effects on retinoid metabolism, function and related diseases.

Authors:  Joseph L Napoli
Journal:  Pharmacol Ther       Date:  2017-01-27       Impact factor: 12.310

3.  Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.

Authors:  Mariella Gruber Filbin; Sukriti K Dabral; Maria F Pazyra-Murphy; Shakti Ramkissoon; Andrew L Kung; Ekaterina Pak; Jarom Chung; Matthew A Theisen; Yanping Sun; Yoko Franchetti; Yu Sun; David S Shulman; Navid Redjal; Barbara Tabak; Rameen Beroukhim; Qi Wang; Jean Zhao; Marion Dorsch; Silvia Buonamici; Keith L Ligon; Joseph F Kelleher; Rosalind A Segal
Journal:  Nat Med       Date:  2013-09-29       Impact factor: 53.440

Review 4.  Retinoic acid signaling and neuronal differentiation.

Authors:  Amanda Janesick; Stephanie Cherie Wu; Bruce Blumberg
Journal:  Cell Mol Life Sci       Date:  2015-01-06       Impact factor: 9.261

5.  All-trans retinoic acid inhibits craniopharyngioma cell growth: study on an explant cell model.

Authors:  Qiang Li; Chao You; Liangxue Zhou; Xiutian Sima; Zhiyong Liu; Hao Liu; Jianguo Xu
Journal:  J Neurooncol       Date:  2013-02-20       Impact factor: 4.130

6.  Integrated genomic analysis of survival outliers in glioblastoma.

Authors:  Sen Peng; Harshil Dhruv; Brock Armstrong; Bodour Salhia; Christophe Legendre; Jeffrey Kiefer; Julianna Parks; Selene Virk; Andrew E Sloan; Quinn T Ostrom; Jill S Barnholtz-Sloan; Nhan L Tran; Michael E Berens
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

7.  Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis.

Authors:  Liraz Levi; Glenn Lobo; Mary Kathryn Doud; Johannes von Lintig; Darcie Seachrist; Gregory P Tochtrop; Noa Noy
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

8.  A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.

Authors:  Christopher G Duncan; Benjamin G Barwick; Genglin Jin; Carlo Rago; Priya Kapoor-Vazirani; Doris R Powell; Jen-Tsan Chi; Darell D Bigner; Paula M Vertino; Hai Yan
Journal:  Genome Res       Date:  2012-08-16       Impact factor: 9.043

9.  Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study.

Authors:  James L Rogers; Elizabeth Vera; Alvina Acquaye; Nicole Briceno; Varna Jammula; Amanda L King; Heather Leeper; Martha M Quezado; Javier Gonzalez Alarcon; Lisa Boris; Eric Burton; Orieta Celiku; Anna Choi; Alexa Christ; Sonja Crandon; Ewa Grajkowska; Nicole Leggiero; Nicole Lollo; Marta Penas-Prado; Jennifer Reyes; Christine Siegel; Brett J Theeler; Michael Timmer; Kathleen Wall; Jing Wu; Kenneth Aldape; Mark R Gilbert; Terri S Armstrong
Journal:  Neurooncol Pract       Date:  2021-04-10

10.  Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.

Authors:  Haihui Jiang; Kefu Yu; Yong Cui; Xiaohui Ren; Mingxiao Li; Guobin Zhang; Chuanwei Yang; Xuzhe Zhao; Qinghui Zhu; Song Lin
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.